Used in conjunction with clinical assessment, the NT-proBNP (N-terminal pro b-type natriuretic peptide) test is a useful biomarker in the diagnosis and management of patients with heart failure.
The new test expands Alere's point-of-care Triage cardiovascular testing solutions.
BNP (b-type natriuretic peptide) and NT-proBNP levels can help doctors differentiate between heart failure and other problems, since the level of natriuretic peptides in the blood increases as chronic heart failure advances.
The Alere Triage NT-proBNP test can aid clinical professionals, diagnosing individuals suspected of having heart failure, assessing the risk of patients with heart failure, assessing the risk of patients with acute coronary syndrome (ACS) and assessing the increased risk for cardiovascular events and mortality in patients with stable coronary artery disease (CAD) who are also at risk of heart failure.
The test is CE marked, which expresses conformity with the requirements of the European IVD Directive and allows distribution within the EU.
